Magdalene Joseph

Magdalene Joseph

Auto-generated profile, based on publicly available information

Magdalene Joseph

Mount Vernon Cancer Centre , Northwood, HA6 2RN

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Immunity
Verified
Journal Article
Open access
CGCarl Graham
Carl Graham
JSJeffrey Seow
Jeffrey Seow
IHIsabella Huettner
Isabella Huettner
HKHataf Khan
Hataf Khan
NKNeophytos Kouphou
Neophytos Kouphou
KDKatie J. Doores
Katie J. Doores
Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To understand how these mutations affect Spike antigenicity, we isolated and characterized >100 monoclonal antibodies targeting epitopes on RBD, NTD, and S2 from SARS-CoV-2-infected individuals. Approximately 45% showed neutralizing activity, of which ∼20% were NTD specific. NTD-specific antibodies formed two distinct groups: the first was highly potent against infectious virus, whereas the second was less potent and displayed glycan-dependant neutralization activity. Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes should be considered when investigating antigenic drift in emerging variants.

20 November 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MJMagdalene Joseph
Magdalene Joseph
DEDeborah Enting
Deborah Enting
Immunosurveillance, which describes the immunologically mediated elimination of transformed cells, has been widely accepted in the context of bladder cancer for many decades with the successful use of Bacillus-Calmette Guerin for superficial bladder cancer since the 1970s. With the emergence of checkpoint inhibitor blockade in the treatment of urothelial cancers, there has been a resurgent interest in the immunology of bladder cancer. The theory of cancer immunoediting proposes that the immune system has both pro-tumorigenic and anti-tumor effects, the balance between the two determining the progression of an individual tumor. However, whilst there is evidence for the action of various immune cell populations in bladder cancer, a cohesive picture of the immune response to bladder cancer and its driving forces are still lacking. Additionally, little is still known about the normal immune landscape of the bladder. Future progress in bladder cancer therapeutic approaches will require a strong foundation in understanding the immunology of this disease. This review considers the evidence for the role of the main immune cell populations, both innate and adaptive, in the immune response to bladder cancer. Recent research and overarching themes in the immune response to bladder cancer are explored. The minimal evidence regarding the normal immune landscape of the human bladder is also summarized to contextualize downstream immune responses. Of specific interest are the innate and myeloid populations, some of which are resident in the human bladder and which have significant effects on downstream adaptive tumor immunity. We discuss factors which restrain the efficacy of populations known to have anti-tumor activity such as cytotoxic T cells, including the constraints on checkpoint blockade. Additionally, the effects on the immune response of tumor intrinsic factors such as the genomic subtype of bladder cancer and the effect of common therapies such as chemotherapy and intravesical Bacillus Calmette-Guerin are considered. A significant theme is the polarization of immune responses within the tumor by a heavily immunosuppressive tumor microenvironment which affects the phenotype of multiple innate and adaptive populations. Throughout, clinical implications are discussed with suggestions for future research directions and therapeutic targeting.

17 March 2021 in medRxiv
Verified
Preprint
Open access
PDF file
LMLeticia Monin-Aldama
Leticia Monin-Aldama
ALAdam G. Laing
Adam G. Laing
MMMiguel Muñoz-Ruiz
Miguel Muñoz-Ruiz
DMDuncan R McKenzie
Duncan R McKenzie
IBIrene del Molino del Barrio
Irene del Molino del Barrio
SISheeba Irshad
Sheeba Irshad
Background The efficacy and safety profile of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in immunocompromised patient populations. Patients with a known cancer diagnosis were hitherto excluded from trials of the vaccines currently in clinical use. Methods This study presents data on the safety and immune efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine in 54 healthy controls and 151 mostly elderly patients with solid and haematological malignancies, respectively, and compares results for patients who were boosted with BNT162b2 at 3 weeks versus those who were not. Immune efficacy was measured as antibody seroconversion, T cell responses, and neutralisation of SARS-CoV-2 Wuhan strain and of a variant of concern (VOC) (B.1.1.7). We also collected safety data for the BNT162b2 vaccine up to 5 weeks following first dose. Findings The vaccine was largely well tolerated. However, in contrast to its very high performance in healthy controls (>90% efficacious), immune efficacy of a single inoculum in solid cancer patients was strikingly low (below 40%) and very low in haematological cancer patients (below 15%). Of note, efficacy in solid cancer patients was greatly and rapidly increased by boosting at 21-days (95% within 2 weeks of boost). Too few haematological cancer patients were boosted for clear conclusions to be drawn. Conclusions Delayed boosting potentially leaves most solid and haematological cancer patients wholly or partially unprotected, with implications for their own health; their environment and the evolution of VOC strains. Prompt boosting of solid cancer patients quickly overcomes the poor efficacy of the primary inoculum in solid cancer patients. Evidence before this study Some cancer patients have been shown to exhibit sustained immune dysregulation, inefficient seroconversion and prolonged viral shedding as a consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Consequently, their exclusion and, in particular, the exclusion of patients receiving systemic anti-cancer therapies, from the registry trials of the 5 approved COVID-19 vaccines raises questions about the efficacy and safety of SARS-CoV-2 vaccination in this patient population. In addition, whilst the change in the UK’s dosing interval to 12-weeks aimed to maximise population coverage, it is unclear whether this strategy is appropriate for cancer patients and those on systemic anti-cancer therapies. Added value of this study We report that the RNA-based SARS-CoV-2 BNT162b2 vaccine administered in cancer patients was well tolerated, and we provide first insights into both antibody and T cell responses to the vaccine in an immunocompromised patient population. Implications of all the available evidence In cancer patients, one dose of 30ug of BNT162b2 yields poor vaccine efficacy, as measured by seroconversion rates, viral neutralisation capacity and T cell responses, at 3- and 5-weeks following the first inoculum. Patients with solid cancers exhibited a significantly greater response following a booster at 21-days. These data support prioritisation of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine. Given the globally poor responses to vaccination in patients with haematological cancers, post-vaccination serological testing, creation of herd immunity around these patients using a strategy of ‘ring vaccination’, and careful follow-up should be prioritised.

9 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ALAdam G. Laing
Adam G. Laing
ALAnna Lorenc
Anna Lorenc
IBIrene Del Molino Del Barrio
Irene Del Molino Del Barrio
ADAbhishek Das
Abhishek Das
MFMatthew Fish
Matthew Fish
AHAdrian C. Hayday
Adrian C. Hayday
Person-to-person transmission of SARS-CoV-2 virus has triggered a global emergency because of its potential to cause life-threatening Covid-19 disease. By comparison to paucisymptomatic virus clearance by most individuals, Covid-19 has been proposed to reflect insufficient and/or pathologically exaggerated immune responses. Here we identify a consensus peripheral blood immune signature across 63 hospital-treated Covid-19 patients who were otherwise highly heterogeneous. The core signature conspicuously blended adaptive B cell responses typical of virus infection or vaccination with discrete traits hitherto associated with sepsis, including monocyte and dendritic cell dampening, and hyperactivation and depletion of discrete T cell subsets. This blending of immuno-protective and immuno-pathogenic potentials was exemplified by near-universal CXCL10/IP10 upregulation, as occurred in SARS1 and MERS. Moreover, specific parameters including CXCL10/IP10 over-expression, T cell proliferation, and basophil and plasmacytoid dendritic cell depletion correlated, often prognostically, with Covid-19 progression, collectively composing a resource to inform SARS-CoV-2 pathobiology and risk-based patient stratification.

9 August 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MJMagdalene Joseph
Magdalene Joseph
YWYin Wu
Yin Wu
RDRichard Dannebaum
Richard Dannebaum
FRFlorian Rubelt
Florian Rubelt
IZIva Zlatareva
Iva Zlatareva
AHAdrian C. Hayday
Adrian C. Hayday
Whereas pathogen-specific T and B cells are a primary focus of interest during infectious disease, we have used COVID-19 to ask whether their emergence comes at a cost of broader B cell and T cell repertoire disruption. We applied a genomic DNA-based approach to concurrently study the immunoglobulin-heavy (IGH) and T cell receptor (TCR) β and δ chain loci of 95 individuals. Our approach detected anticipated repertoire focusing for the IGH repertoire, including expansions of clusters of related sequences temporally aligned with SARS-CoV-2–specific seroconversion, and enrichment of some shared SARS-CoV-2–associated sequences. No significant age-related or disease severity–related deficiencies were noted for the IGH repertoire. By contrast, whereas focusing occurred at the TCRβ and TCRδ loci, including some TCRβ sequence–sharing, disruptive repertoire narrowing was almost entirely limited to many patients aged older than 50 y. By temporarily reducing T cell diversity and by risking expansions of nonbeneficial T cells, these traits may constitute an age-related risk factor for COVID-19, including a vulnerability to new variants for which T cells may provide key protection.

1 January 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
MJMagdalene Joseph
Magdalene Joseph
FCFidelma Cahill
Fidelma Cahill
HWHarriet Wylie
Harriet Wylie
DEDeborah Enting
Deborah Enting
MHMieke Van Hemelrijck
Mieke Van Hemelrijck
AHAdrian Hayday
Adrian Hayday
Background Bladder cancer is known to be immunologically modulated since the 1970s when Bacille-Calmette Guerin (BCG) was shown effective in treating superficial bladder tumours. Moreover, immune checkpoint inhibitors have now demonstrated survival benefit in advanced bladder cancer and are considered standard treatment for chemotherapy-resistant disease. Of special interest in immuno-oncology are unconventional, innate-like T cells bearing the gamma delta T cell receptor. They are found enriched at the epithelial surfaces and are capable of rapid, non-MHC restricted responses to various stressors. These cells are found to be the strongest correlate of positive prognosis in a recent transcriptomic analysis of over 18,000 tumours 1. Studies on mouse models of bladder cancer have shown that survival can be prolonged by injecting gamma delta T cells intravesically2 and that responses to BCG are abolished in gamma delta T cell knockout mice suggesting an anti-tumorigenic role3. This project aims to characterise the presence and phenotype of gamma delta T cells in the blood and tissue in human bladder cancer to understand their contribution to the immune regulation of the disease. Methods Mononuclear cells from peripheral blood of healthy, age-matched controls and patients with bladder cancer will be phenotyped by flow cytometry with a focus on gamma delta T cells to elucidate the differences between health and disease. Tissue infiltrating lymphocytes will also be isolated from bladder tumour tissue and peri-tumoural normal tissue using a cell-foam matrix culture system described previously4 and phenotyped in a similar fashion. Phenotypes from flow cytometry will be confirmed by polymerase chain reaction targeting the markers of interest. The localisation of gamma delta T cells within the tissue will be examined by immunohistochemistry. Results Preliminary results from healthy volunteers show differences in the expression of various markers between different gamma delta T cell populations and differences between fresh and frozen samples. Conclusion The aim is to understand gamma delta T cell mediated immune regulation of bladder cancer.